Viz.ai, Inc., an applied artificial intelligence healthcare company, announced today that new data on its approved and investigational technologies for acute ischemic and hemorrhagic stroke will be presented during the 4th European Stroke Organization Conference (ESOC) from May 16-18 in Gothenburg, Sweden.
Viz.ai, Inc., an applied artificial intelligence healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has cleared Viz CTP through the 510(k) pathway. Viz CTP offers image processing software to view and analyze functional and dynamic CT perfusion images. This clearance offers healthcare providers another important tool for automated cerebral-image analysis.
Viz.ai Inc. solutions and deployments based on Amazon Web Services (AWS) were reviewed (audited) by AWS, and found to match the highest requirements for security, reliability, performance efficiency, operational excellence and cost optimization set by the AWS Well-Architected Framework. The cover letter of the audit report, provided to Viz.ai by AWS reads:
... The Well-Architected review has been insightful on our part, and we hope you will find it useful as well. I’ve personally found your workload impressive and outstanding, both from the technological point of view, and because of the high standards ...
... Overall, your system is impressive and Well-Architected in many aspects. As a matter of fact, you are Well-Architected right now already ...
Viz.ai, Inc., an applied artificial intelligence healthcare company announced that the U.S. Food and Drug Administration (FDA) has granted a De Novo request for the first-ever Computer-Aided Triage and Notification Platform to identify Large Vessel Occlusion (LVO) strokes in CTA imaging. This regulatory clearance compliments Viz.ai's recent European CE Mark for the product in January 2018.
Viz.ai, a revolutionary Direct-to-Intervention healthcare company, today announced that Conrad Yiu has been named as its Chief Commercial Officer (CCO). As CCO, Yiu has responsibility for all customer-facing activities, including global sales, marketing, product development, clinical research, business development, and customer support. Yiu will report directly to Chris Mansi, M.D., Viz.ai’s President and CEO.